TrialDrug design, development and therapy2021

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TPN171H, a Novel Phosphodiesterase Type 5 Inhibitor, in Healthy Subjects.

Hongjie Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.